Boehringer Ingelheim (China)

Early versus delayed or no empagliflozin initiation after hospitalisation for heart failure in the United States: A target trial emulation

BACKGROUND: Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are a foundational therapy for heart failure (HF), yet initiation is frequently delayed in clinical practice. Evidence comparing outcomes associated with early versus delayed or no initiation following hospitalisatio...